Skin Cancer

Clinical Trials

Below is a list of Skin Cancer clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Comparison of Infection Rates Between Two Surgical Sites
The intent of this proposed prospective observational cohort study is to determine if there is a difference in the incidence of corneal toxicity and/or ototoxicity in study subjects undergoing Mohs micrographic surgery (MMS) on the face if a povidone-iodine preparation is used pre-operatively as compared to a chlorhexidine-alcohol preparation.
Read more

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
Read more

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
OBJECTIVES: Primary - To assess whether there is sufficient promise of an impact of the addition of everolimus to the combination of carboplatin, paclitaxel, and bevacizumab on progression-free survival that it would be recommended for further testing in patients with metastatic malignant melanoma.
Read more

Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck
The goal of this study is to see if patients can tolerate HBO therapy up to five days a week. Three patients in Arm 1 (HBO on Monday and Friday) will be observed throughout their course of concomitant radiation, chemo and hyperbaric therapy.
Read more

Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
PRIMARY OBJECTIVES: I. To assess the clinical activity of timed administration of TMZ therapy in patients with stage IV melanoma who have or have not received prior chemotherapy for metastatic melanoma. SECONDARY OBJECTIVES: I.
Read more

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
OBJECTIVES: Primary - To evaluate recurrence-free survival (RFS) between patients randomized to receive post-operative adjuvant ipilimumab versus those randomized to receive high-dose recombinant interferon alfa-2b (HDI). - To evaluate overall survival (OS) between patients randomized to receive pos-toperative adjuvant ipilimumab versus those randomized to receive HDI.
Read more

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
OBJECTIVES: Primary - Determine the safety of rituximab, yttrium Y 90 ibritumomab tiuxetan, high-dose melphalan, and autologous peripheral blood stem cell transplantation in patients with previously treated multiple myeloma. - Determine the effect of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonotypic B-cells at baseline and at B-cell recovery in these patients.
Read more

Stage IV Surgery Versus Best Medical Therapy
This study is designed to examine the impact of surgical resection versus medical therapy as initial treatment therapy for patients with Stage IV melanoma. Surgical resection is thought to be efficacious in highly selected patients with solitary metastases, but not in patients with multiple sites of metastases.
Read more

Temozolomide or MEK Inhibitor AZD6244 (Selumetinib) in Treating Patients With Metastatic Melanoma of the Eye
OBJECTIVES: Primary - To assess the progression-free survival (PFS) in three separate patient populations with metastatic uveal melanoma treated with temozolomide vs MEK inhibitor AZD6244 (selumetinib). Secondary - To assess overall survival (OS). - To assess the overall response rate (RR).
Read more